UOC
ACRV icon

UBS O'Connor’s Acrivon Therapeutics ACRV Stock Holding History

UBS O'Connor’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,576
Closed -$31.6K – 369
2025
Q1 		$31.6K Sell
15,576
-87,208
-85% -$470K ﹤0.01% 295
2024
Q4 		$619K Buy
102,784
+23,535
+30% +$171K 0.02% 264
2024
Q3 		$555K Sell
79,249
-26,000
-25% -$205K 0.01% 337
2024
Q2 		$610K Sell
105,249
-21,700
-17% -$175K 0.02% 354
2024
Q1 		$908K Buy
126,949
+33,506
+36% +$156K 0.03% 285
2023
Q4 		$460K Sell
93,443
-11,557
-11% -$61K 0.01% 360
2023
Q3 		$1M Buy
105,000
+5,000
+5% +$57.8K 0.02% 331
2023
Q2 		$1.3M Buy
+100,000
New +$1.21M 0.03% 357

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS O'Connor's ACRV Position: Q2 2025 in Review

UBS O'Connor sold out of Acrivon Therapeutics (ACRV) in Q2 2025, closing a stake of 15,576 shares — an estimated $31.6K sold.

UBS O'Connor first reported a position in ACRV in Q2 2023 and held it in 8 quarters. The position peaked at $1.3M in Q2 2023. 53 funds tracked by Wall St. Rank hold ACRV as of Q2 2025.

  • UBS O'Connor reported no remaining Acrivon Therapeutics position as of Q2 2025 after selling out during the quarter.
  • UBS O'Connor sold 15,576 Acrivon Therapeutics shares in Q2 2025, an estimated $31.6K.
  • UBS O'Connor first reported a position in Acrivon Therapeutics in Q2 2023 and held it in 8 quarters.
  • UBS O'Connor's Acrivon Therapeutics position peaked at $1.3M in Q2 2023.
  • 53 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2025.

Based on UBS O'Connor's 13F filing for Q2 2025, filed 14 Aug 2025.